- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT00720356
Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
A Phase II Study of Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma Without MGMT Promoter Methylation
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving bevacizumab together with erlotinib may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving bevacizumab together with erlotinib works after radiation therapy and temozolomide in treating patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
OBJECTIVES:
Primary
- To determine the overall survival of patients with newly diagnosed glioblastoma multiforme (GBM) with unmethylated MGMT promoter treated with bevacizumab and erlotinib hydrochloride after radiotherapy and temozolomide.
Secondary
- To determine the 12- and 24-month progression-free survival (PFS) of patients with newly diagnosed GBM with unmethylated MGMT promoter treated with this regimen.
- To assess radiographic response rates.
- To perform correlative tissue assays.
- To collect safety data on the combination of bevacizumab and erlotinib hydrochloride in patients with newly diagnosed GBM with unmethylated MGMT promoter treated with bevacizumab and erlotinib hydrochloride after radiotherapy and temozolomide.
OUTLINE: This is a multicenter study.
Patients undergo radiotherapy (either intensity-modulated radiation therapy or 3-D conformal radiotherapy) once daily 5 days a week and receive oral temozolomide concurrently with radiotherapy once daily for 6 weeks (as planned). Patients whose tumor has a methylated MGMT promoter are removed from study.
Approximately 4 weeks after completion of radiotherapy and temozolomide, patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral erlotinib hydrochloride once daily on days 1-28. Treatment with bevacizumab and erlotinib hydrochloride repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed at approximately 30 days and then every 3 months thereafter.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 2
Yhteystiedot ja paikat
Opiskelupaikat
-
-
California
-
Los Angeles, California, Yhdysvallat, 90048
- Cedars-Sinai Medical Center
-
-
Florida
-
Orlando, Florida, Yhdysvallat, 32806-2134
- M.D. Anderson Cancer Center at Orlando
-
-
Illinois
-
Chicago, Illinois, Yhdysvallat, 60611-3013
- Northwestern University, Northwestern Medical Faculty Foundation
-
Evanston, Illinois, Yhdysvallat, 60201-1781
- Evanston Hospital
-
-
South Carolina
-
Charleston, South Carolina, Yhdysvallat, 29425
- Hollings Cancer Center at Medical University of South Carolina
-
-
Texas
-
Dallas, Texas, Yhdysvallat, 75246
- Neuro-Oncology Associates at Baylor University Medical Center, Dallas
-
Houston, Texas, Yhdysvallat, 77030-4009
- M.D. Anderson Cancer Center at University of Texas
-
Houston, Texas, Yhdysvallat, 77030
- The Methodist Hospital Neurological Institute
-
-
Washington
-
Seattle, Washington, Yhdysvallat, 19024
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
DISEASE CHARACTERISTICS:
- Histologically confirmed newly diagnosed glioblastoma multiforme (GBM) or gliosarcoma
- Undergoing or plan to undergo treatment with radiotherapy and concurrent temozolomide for 6 weeks
Unmethylated MGMT promoter status must be determined before completing radiotherapy
- Tumor must be MGMT negative to receive bevacizumab and erlotinib hydrochloride
Patients who are post biopsy or tumor resection allowed provided a post-operative MRI is done no more than 96 hours after surgery (in order for an accurate assessment to be done post radiotherapy):
- Evaluable or measurable disease after resection of recurrent tumor is not mandated for eligibility
Patients who started radiotherapy and temozolomide prior to study entry are eligible as long as the gene methylation status is determined before starting bevacizumab and erlotinib hydrochloride
- Radiotherapy plans need to be verified to confirm the treatment plan meets the study requirement based on the PI assessment
- No progressive disease based on MRI or CT scan per the investigators assessment
PATIENT CHARACTERISTICS:
- Karnofsky performance status 70-100%
- Life expectancy > 12 weeks
- WBC > 3,000/μL
- ANC > 1,500/mm³
- Platelet count > 100,000/mm³
- Hemoglobin > 10 g/dL
- SGOT/SGPT < 3 times upper limit of normal (ULN)
- Bilirubin < 3 times ULN
- Creatinine < 1.5 mg/dL
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3 months after completion of study treatment
- No significant medical illness that, in the investigator's opinion, cannot be adequately controlled with appropriate therapy, would compromise the patient's ability to tolerate this therapy, or any disease that will obscure toxicity or dangerously alter drug metabolism
No proteinuria at screening, as demonstrated by either of the following:
- Urine protein:creatinine (UPC) ratio < 1.0
- Urine dipstick for proteinuria < 2+ OR ≤ 1g protein by 24-hour urine collection
- No inadequately controlled hypertension (defined as systolic blood pressure > 150 mm Hg and/or diastolic blood pressure > 100 mm Hg) on antihypertensive medications
- No history of hypertensive crisis or hypertensive encephalopathy
- No New York Heart Association class II-IV congestive heart failure
- No history of myocardial infarction or unstable angina within 6 months prior to study enrollment
- No history of stroke or transient ischemic attack within 6 months of study enrollment
- No symptomatic peripheral vascular disease
- No significant vascular disease (i.e., aortic aneurysm or aortic dissection)
- No evidence of bleeding diathesis or coagulopathy
- No significant traumatic injury within 28 days prior to study enrollment
- No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment
- No serious, nonhealing wound, ulcer, or bone fracture
No known HIV positivity
- HIV testing is not required for study participation
- No history of any other cancer (except nonmelanoma skin cancer or carcinoma in situ of the cervix), unless in complete remission and off of all therapy for that disease for a minimum of 3 years
PRIOR CONCURRENT THERAPY:
- No chemotherapy is allowed prior to starting radiotherapy and temozolomide, including polifeprosan 20 with carmustine implant (Gliadel wafers)
- No major surgical procedure or open biopsy within 28 days prior to study enrollment or the anticipation of need for major surgical procedure during the course of the study
- No core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment
Concurrent nonenzyme-inducing anticonvulsants allowed
- More than 2 weeks (before starting erlotinib hydrochloride and bevacizumab) since prior and no concurrent enzyme-inducing anticonvulsant
- No other concurrent experimental agents
- Not concurrently participating in other clinical trials
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: Treatment
erlotinib and bevacizumab
|
10mg/kg administered intravenously every 2 weeks
Muut nimet:
150 mg/daily orally
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Overall Survival
Aikaikkuna: From start of treatment, during treatment and every 3 months following the end of treatment until death. Median follow up at time of OS data was 33 months.
|
Overall survival (OS) will be measured from the start of treatment until death from any cause.
At data cut off patients remaining alive will be censored at the last known date of contact.
|
From start of treatment, during treatment and every 3 months following the end of treatment until death. Median follow up at time of OS data was 33 months.
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Progression-free Survival at 12 Months
Aikaikkuna: At 12 months from start of treatment
|
Progression free survival (PFS) will be assessed by CT or MRI scan using McDonald criteria.
Progressive disease (PD) is defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).
Stable or increased dose of steroids.
PFS will be measured from the start of treatment until first documentation of PD or death.
|
At 12 months from start of treatment
|
Response Rate (RR)
Aikaikkuna: From the start of treatment, every 2 cycles (1 cycle = 28 days) during treatment until progressive disease
|
Response Rate (RR) will be defined as the best response seen during treatment measured by CT/MRI scan every 8 weeks during treatment using McDonald Criteria. CR=Complete disappearance of all measurable and evaluable disease. No new lesions. No evidence of non-evaluable disease. Patients off steroids. PR=Greater than or equal to 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable disease. No new lesions. Stable/decreased dose of steroids. Stable/No Response=Does not qualify for CR, PR, or progression. The designation of Stable/No Response requires a minimum of 8 weeks duration. Stable/decreased dose of steroids. Progressive disease = 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease), worsening of evaluable disease, new lesions/site, failure to return for evaluation due to death or deteriorating condition. |
From the start of treatment, every 2 cycles (1 cycle = 28 days) during treatment until progressive disease
|
Safety of the Combination of Erlotinib and Bevacizumab in This Patient Population
Aikaikkuna: From the start of treatment, at the beginning of every cycle (1 cycle = 28 days) during treatment until 30 days after completion of treatment for up to 49 cycles.
|
Toxicity data for combination treatment of erlotinib and bevacizumab will be collected on day 1 of every cycle (1 cycle = 28 days) during treatment according to the National Cancer Institute's Common Toxicity Criteria for adverse events version 3.0 (CTCAE v3.0). In general adverse events (AEs) will be graded according to the following: Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE |
From the start of treatment, at the beginning of every cycle (1 cycle = 28 days) during treatment until 30 days after completion of treatment for up to 49 cycles.
|
Progression Free Survival at 18 Months
Aikaikkuna: At 18 months from start of treatment
|
Progression free survival (PFS) will be assessed by CT or MRI scan using McDonald criteria.
Progressive disease (PD) is defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).
Stable or increased dose of steroids.
PFS will be measured from the start of treatment until first documentation of PD or death.
|
At 18 months from start of treatment
|
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Changes in Tumor Blood Flow Based on MR Perfusion
Aikaikkuna: Prior to study treatment (after surgery, but before radiation), just before study treatment (within 14 days prior to first treatment) and then every 2 cycles during study treatment, where 1 cycle equals 28 days for a maximum of 49 cycles.
|
Data from consenting patients will be used to assess of changes in tumor blood flow based on MR perfusion using MRI scans.
Two scans will be completed prior to treatment on study; the first after surgery buta before radiation, the second within 14 days before starting combination treatment or erlotinib and bevacizumab.
Then scans will be completed every 2 cycles during treatment, where one cycle equals 28 days.
|
Prior to study treatment (after surgery, but before radiation), just before study treatment (within 14 days prior to first treatment) and then every 2 cycles during study treatment, where 1 cycle equals 28 days for a maximum of 49 cycles.
|
Gene Methylation Studies (Optional)
Aikaikkuna: At baseline and then plasma only will be collected every odd cycle (1 cycle = 28 days) during treatment for a maximum of 49 cycles.
|
Tissue and plasma collected from consenting patients in the study will be used to correlate tumor tissue with imaging and outcomes.
Tissue will be collected before treatment on study begins and plasma will be collected the first day of treatment (before treatment) and every odd cycle after that, whilst on study treatment.
Tissue and plasma analysis will be correlated with patients imaging results and response to to treatment
|
At baseline and then plasma only will be collected every odd cycle (1 cycle = 28 days) during treatment for a maximum of 49 cycles.
|
Yhteistyökumppanit ja tutkijat
Sponsori
Yhteistyökumppanit
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Hermoston sairaudet
- Neoplasmat histologisen tyypin mukaan
- Neoplasmat
- Neoplasmat sivustoittain
- Kasvaimet, rauhas- ja epiteelikasvaimet
- Astrosytooma
- Glioma
- Neoplasmat, neuroepiteliaaliset
- Neuroektodermaaliset kasvaimet
- Neoplasmat, sukusolut ja alkiot
- Kasvaimet, hermokudos
- Glioblastooma
- Hermoston kasvaimet
- Keskushermoston kasvaimet
- Gliosarkooma
- Huumeiden fysiologiset vaikutukset
- Farmakologisen vaikutuksen molekyylimekanismit
- Entsyymin estäjät
- Antineoplastiset aineet
- Antineoplastiset aineet, immunologiset
- Angiogeneesin estäjät
- Angiogeneesiä moduloivat aineet
- Kasvuaineet
- Kasvun estäjät
- Proteiinikinaasin estäjät
- Erlotinibihydrokloridi
- Bevasitsumabi
Muut tutkimustunnusnumerot
- NU 07C3 (Muu tunniste: Northwestern University)
- BTTC08-01 (Muu tunniste: U.T. M.D. Anderson Cancer Center)
- STU00002792 (Muu tunniste: Northwestern University IRB)
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset bevacizumab
-
Centre Hospitalier Universitaire de NiceLopetettu
-
Northwell HealthValmisGlioblastoma Multiforme | Anaplastinen astrosytoomaYhdysvallat
-
Istituto Scientifico Romagnolo per lo Studio e...ValmisMetastaattinen paksusuolen syöpäItalia
-
Hospital Universitari de BellvitgeInstituto de Salud Carlos IIILopetettuPaksusuolen syöpä | Paksusuolisyövästä peräisin oleva ei-leikkattava metastaasiEspanja
-
University of NottinghamTuntematonSarveiskalvon uudissuonittuminen
-
University of California, San DiegoLopetettu
-
National Cancer Institute (NCI)NRG OncologyValmisPahanlaatuinen munasarjojen epiteelisuumori | Munasarjan gynandroblastooma | Munasarjan Sertoli-Leydig-solukasvain | Munasarjan sukupuolinuorakasvain rengasmaisilla tubuluksilla | Munasarjan steroidisolukasvain | Munasarjan granulosasolukasvain | Munasarjan sukupuolinuora-stromakasvain | Munasarjojen sukupuolinuora-stromakasvain...Yhdysvallat
-
University of California, San FranciscoMerck Sharp & Dohme LLCValmisIV vaiheen kolorektaalisyöpä AJCC v7 | IVA-vaiheen kolorektaalisyöpä AJCC v7 | IVB-vaiheen kolorektaalisyöpä AJCC v7 | Mikrosatelliitti vakaa | Vaiheen III paksusuolensyöpä AJCC v7 | Vaiheen IIIB kolorektaalisyöpä AJCC v7 | Vaiheen IIIC kolorektaalisyöpä AJCC v7 | Mismatch Repair Protein ProficientYhdysvallat
-
GOG FoundationNational Cancer Institute (NCI)ValmisToistuva munanjohtimien karsinooma | Toistuva munasarjasyöpä | Toistuva primaarinen peritoneaalinen syöpäYhdysvallat